This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $423,500.00 to the University of Rochester to conduct research on the role of insulin-like growth factor binding protein 7 (IGFBP7) in the pathogenesis and treatment of scleroderma-associated fibrosis and pulmonary hypertension. The award, with a performance period from January 1, 2025 to December 31, 2026, will enable the university to investigate scientific advances in this area that could improve health outcomes for military service members and the broader public. The university has extensive expertise in medical research and a track record of successfully executing federally funded initiatives across a range of disciplines.
Generated 2/25/25, 1:45 AM